Association of interleukin 1 beta (IL-1β) polymorphism with mRNA expression and risk of non small cell lung cancer

Introduction: Interleukin 1 beta (IL-1 beta), a key proinflammatory cytokine encoded by the interleukin 1 beta gene, has been associated with chronic inflammation and plays an important role in lung inflammatory diseases including lung cancer. Elevated levels of Interleukin 1proteins, in particular interleukin 1 beta greatly enhance the intensity of the inflammatory response. Aim: To study the role of interleukin 1 beta-31C > T and -511 T > C polymorphismin the pathogenesis of non small cell lung cancer (NSCLC). Materials and methods: One hundred and ninety non small cell lung cancer patients and 200 healthy age, sex, smoking and dwelling matched controls were used for polymorphic analysis by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) followed by sequencing. Normal tissues of 48 histopathologically confirmed non small cell lung cancer patients were taken for mRNA expression analysis. Quantitation of interleukin 1 beta was carried out by quantitative real time PCR. Result: The T/T genotype of interleukin 1 beta-31 genewas significantly associated with increased risk of NSCLC [(P = 0.001, OR - 2.8 (95% CI 1.52-5.26)]. The interleukin 1 beta - 511 T > C does not show any difference between the NSCLC and control group (P = 0.3, OR - 0.72 (95% CI 0.41-1.28). Quantitative analysis of mRNA showed significant association with interleukin 1 beta T allele as compared to the interleukin 1 beta-31C allele (P = 0.006). Conclusion: We conclude that lung cancer risk genotype interleukin 1 beta-31TT results in increased expression of interleukin 1 beta mRNA in lung cancer patients. Our data suggest that this genotype (IL1 beta -31TT) in the interleukin 1 beta regulatory region provide a microenvironment with elevated inflammatory stimuli and thus increasing the risk for lung cancer. (C) 2013 The Authors. Published by Elsevier B.V. All rights reserved.